drugset
drugset / Trial / NCT00004474

Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

NCT00004474 ↗

Phase 3 Completed 224 enrolled Roswell Park Cancer Institute
RandomizedParallel-groupTreatment

Summary

OBJECTIVES: I. Compare outcome, including graft failure, graft versus host disease, and survival of HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide with or without antithymocyte globulin as a conditioning regimen.

Timeline

Start
1998-09
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous

Indications

aplastic anemia